•
Sep 30, 2023

Sera Prognostics Q3 2023 Earnings Report

Reported financial results for the third quarter of 2023, with a focus on cost reduction and strategic commercial initiatives.

Key Takeaways

Sera Prognostics reported Q3 2023 revenue of $42,000, a decrease from $87,000 in the same period of 2022. The company's net loss was $7.2 million, an improvement compared to $10.7 million in Q3 2022. Management completed planned cost reduction activities to extend cash runway through most of 2027.

Permanent President and CEO and CFO appointments for Zhenya Lindgardt and Austin Aerts were approved.

Management team completed planned cost reduction activities to extend cash runway through most of 2027.

Scaling care coordination offering and providing it for institutional customers for women identified as high-risk for preterm birth using PreTRM test.

New high-low risk predictor product moved into next phase of market research in preparation for clinical validation.

Total Revenue
$42K
Previous year: $87K
-51.7%
EPS
-$0.23
Previous year: -$0.35
-34.3%
Gross Profit
-$2K
Previous year: $29K
-106.9%
Cash and Equivalents
$9.66M
Previous year: $38.8M
-75.1%
Free Cash Flow
-$7.62M
Previous year: -$9.15M
-16.7%
Total Assets
$90.1M
Previous year: $117M
-22.7%

Sera Prognostics

Sera Prognostics

Forward Guidance

The company is laying the groundwork for a reinvigorated commercial focus designed to cost-effectively target increased test adoption through institutional customer focus and care coordination program, and are exploring potential product and partnership pathways to expand commercial revenue.